News
Researchers from the VHIR and IRBLleida validate the new antitumor ABTL0812 as a therapeutic strategy to fight against endometrial cancer
This drug is capable of killing cancer cells, but not healthy endometrial cells. ABTL0812, developed by the Catalan company AbilityPharma, is already in clinical phase 2 in combination with chemotherapy to treat 40 patients with endometrial cancer.
More than 350 professionals are trained in biomedical porcine model research at CREBA the center of the IRBLleida in 2018
Last year, 5 new projects were started in the facilities ―to investigate kidney disease, laparoscopic surgery for the repair of hernias and the treatment of aneurysms, among others.
The Antoni Rubies Restaurant and the IRBLleida sign a collaboration agreement
The Biomedical Research Institute of Lleida (IRBLleida) and the Antoni Rubies Restaurant sign a collaboration agreement for the first time...
A study led by researchers from Lleida and Reus demonstrates the need to inform in more detail about the benefits and adverse effects of early detection of breast cancer in order to make informed decisions
The InforMa study ―propulsed by the University of Lleida (UdL), the Rovira i Virgili University (URB) and the Biomedical Research Institute of Lleida (IRBLleida)― promotes the participation of women in the decisions and strategies of population programs
